Erythropoietic stimulating agents

Bibliography

• Carnot P, DeFlandre C. Sur l'activité hemopoietique du serum au cours de la regeneration du sang. CR Acad Sci (Paris) 1906;143:384-6
   Google Scholar
• Lin FK, Suggs S, Lin CH, Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;92:7880-4
   Google Scholar
• Jacobs K, Shoemaker C, Rudersdorf R, Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 1985;313:806-10
   PubMed Web of Science ®Google Scholar
• Erslev AJ. Erythopoietin N Engl J Med 1991;324:1339-49
   PubMed Web of Science ®Google Scholar
• Michiels C, Minet E, Mottet D, Raes M. Regulation of gene expression by oxygen: NF-kB and HIF, two extremes Free Radic Biol Med 2002;33:1331-42
   Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H, HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8
   PubMed Web of Science ®Google Scholar
• Jakkola P, Mole DR, Tian YM, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitynilation complex by O2 regulated prolyl hydroxylation Science 2001;292:468-72
   PubMed Web of Science ®Google Scholar
• Epstein AC, Gleadl JM, McNeill MI, C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 2001;107:43-54
   PubMed Web of Science ®Google Scholar
• Ehleben W, Porwol T, Faudrey J, Cobalt and deferioxamine reveal crucial members in the oxygen sensing pathway in HepG2 cells. Kidney Int 1997;51:483-97
   PubMed Web of Science ®Google Scholar
• Zelko IN, Folz RJ. Extracellular superoxide dismutase functions as a major repressor of hypoxia-induced erythropoietin gene expression. Endocrinology 2005;146:332-40
   PubMed Web of Science ®Google Scholar
• Takeda K, Aguila HL, Parikh NS, Regulation of adult erythropoiesis by proxyl hydroxylase domain proteins. Blood 2008;111:3229-35
   PubMed Web of Science ®Google Scholar
• Suzuki N, Ohneda O, Takahashi S, Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002;100:2279-88
   PubMed Web of Science ®Google Scholar
• Remi I, Wilson IA, Michnick JW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999;283:990-3
   PubMed Web of Science ®Google Scholar
• Zhang YL, Radhakrishman ML, Lu X, Symmetric signaling by an asymmetric 1 erythropoietin : 2 erythropoietin receptor complex. Mol Cell 2009;33:266-74
   PubMed Web of Science ®Google Scholar
• Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004;9(Suppl 5):18-30
   PubMed Web of Science ®Google Scholar
• Wojchowski DM, Gregory RC, Miller CP, Signal transduction in the erythropoietin system. Exp Cell Res 1999;253:143-56
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005;434:1144-8
   PubMed Web of Science ®Google Scholar
• Langmore GD, You Y, Molden J, Redundant and selective roles for erythropoietin receptor tyrosines in erythropoiesis in vivo. Blood 1998;91:870-8
   PubMed Web of Science ®Google Scholar
• Zang H, Sato K, Nakajima H, The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis. EMBO J 2001;20:3156-66
   PubMed Web of Science ®Google Scholar
• Menon MP, Karur V, Bogacheva O, Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343.Stat5 axis. J Clin Invest 2006;116:683-94
   PubMed Web of Science ®Google Scholar
• Menon MP, Fang J, Wojchowski DM. Core erythropoietin signals for late erythroblasts development. Blood 2006;107:2662-72
   PubMed Web of Science ®Google Scholar
• Grebien F, Kerenyi MA, Kolbe T, Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood 2008;111:4511-22
   PubMed Web of Science ®Google Scholar
• Papatheofanis FJ, McKenzie RS, Mody SH, Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 2006;22:837-42
   PubMed Web of Science ®Google Scholar
• Schellekens H. Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol 2008;21:497-502
   PubMed Web of Science ®Google Scholar
• Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-19
   PubMed Web of Science ®Google Scholar
• Heatherington AC. Clinical pharmacokinetic properties of rHuEpo: a review. In: Molineux G, Foot MA, Ellliott SG, editors, Erythropoietins and erythropoiesis molecular, cellular, preclinical, and clinical biology. Birkauser Basel: Boston; 2003. p. 87-112
   Google Scholar
• Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008;36:1573-84
   PubMed Web of Science ®Google Scholar
• Casadevall N, Nataf J, Viron B, Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75
   PubMed Web of Science ®Google Scholar
• Bennett CL, Luminari S, Nissenson AR, Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-8
   PubMed Web of Science ®Google Scholar
• McKoy JM, Stonecash RE, Courneyor D, Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-62
   PubMed Web of Science ®Google Scholar
• Llop E, Gutierrez-Gallego R, Segura J, Structural analysis of the glycosylation gene-activated erythropoietin (epoetin delta, Dynepo). Anal Biochem 2008;383:243-54
   PubMed Web of Science ®Google Scholar
• Smith WB, Dowell JA, Pratt RD. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin Ther 2007;7:1368-80
   Web of Science ®Google Scholar
• Frei U, Kwan J, Spinowitz B and the Epoetin Delta 3002 Study GroupAnemia management with subcutaneous epoetin delta in patients with chronic kidney disease(predialysis, hemodialysis, peritoneal dialysis): results of an open-label, I-year study. BMC Nephrol 2009;5:1-8
   Google Scholar
• Spinowitz BS. Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta. Haematologica 2008;93:761-4
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Asher S. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-21
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, Derbopoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
   PubMed Web of Science ®Google Scholar
• Agoram B, Aoki K, Doshi S, Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietic receptor-mediated pathways may play a major role. J Pharmacol Sci 2008;98:2198-221
   Web of Science ®Google Scholar
• Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006;281:2024-32
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O, Pharmacokinetics of novel erythropoiesis stimulating protein compared epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Padhi D, Jang G. Pharmacology of darbopoetin alfa. Nephrol Dial Transplant 2007;22(Suppl 4):2-9
   Google Scholar
• Jang G. Darbopoetin alfa (Aranesp) pharmacokinetics is comparable in chronic kidney disease (CKD) patients receiving and not receiving dialysis, in pediatric patients and in healthy adults. Paper presented at: ASN 38th Annual Renal Week Meeting; 8 – 13 November 2005; Philadelphia, PA
   Google Scholar
• Allon M, Kleinman K, Walezyk M. Pharmacokinetics and pharmacodynamics of darbopoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002;72:546-55
   PubMed Web of Science ®Google Scholar
• Macdougall IC. CERA (continuous erythropoietin recptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-40
   PubMedGoogle Scholar
• Jarsch M, Brandt M, Lanzendorfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of CERA and epoetin beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008;81:63-9
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Robson R, Opatrua S, Pharmacokinetics and pharmacodymamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-15
   PubMed Web of Science ®Google Scholar
• Fishbane S, Liogier X, Dougherty FC, Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol 2007;47:1390-7
   PubMed Web of Science ®Google Scholar
• Levin NW, Fishbane S, Canedo FV, ; on behalf of the MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomized non-inferiority trial (MAXIMA). Lancet 2007;370:1415-21
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Walker R, Provenzano R, ; on behalf of the ARCTOS study investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trials. Clin J Am Soc Nephrol 2008;3:334-47
   Google Scholar
• Canaud B, Mingardi G, Braun J, ; on behalf of the STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable hemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008;23:3654-61
   PubMed Web of Science ®Google Scholar
• Aggarwal S. What's fueling the biotech engine-2007. Nat Biotechnol 2008;26:1227-33
   PubMed Web of Science ®Google Scholar
• Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23
   PubMed Web of Science ®Google Scholar
• Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program 2008:159-65
   PubMedGoogle Scholar
• Miller CB, Jones RJ, Piantadosi S, Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92
   PubMed Web of Science ®Google Scholar
• McClellan W, Aronoff SL, Bolton WK. The presence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10
   PubMed Web of Science ®Google Scholar
• Bahlmann KH, Kielstein JT, Haller H, Fliser D. Erythropoietin and progression of CKD. Kidney Int Suppl 2007;107:521-5
   Google Scholar
• Basile JN. Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease. South Med J 2007;100:1200-7
   PubMed Web of Science ®Google Scholar
• Testa De Maria R, Zeuner A, Eramo A, Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999;401:489-93
   PubMed Web of Science ®Google Scholar
• Wang CQ, Udupa DA, Lipschitz DA. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol 1995;162:134-8
   PubMed Web of Science ®Google Scholar
• Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p 55 and p75 TNF receptors. Blood 1995;85:989-96
   PubMed Web of Science ®Google Scholar
• Dufour C, Cascione A, Sahn J, TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 2003;102:2053-9
   PubMed Web of Science ®Google Scholar
• Xiao W, Koizumi K, Nishio M, Tumor necrosis factor-l alpha inhibits generation of glycophorin-A+ cells by CD34+ cells. Exp Hematol 2002;30:1238-47
   PubMed Web of Science ®Google Scholar
• Buck I, Morceau F, Grigorakaki C, Linking anemia to inflammation and cancer. The crucial role of TNF-a. Biochem Pharmacol 2009;77:1572-9
   PubMed Web of Science ®Google Scholar
• Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009;1790:682-93
   PubMed Web of Science ®Google Scholar
• Theurl I, Mattle V, Seifert M, Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia and chronic disease. Blood 2006;107:4142-8
   PubMed Web of Science ®Google Scholar
• Minoo P, Zadeh MM, Rottapel R, A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosine's in cytokine signaling. Blood 2004;103:1398-407
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Abdulhadi MH, Browne JK, Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Int Med 1989;111:992-1000
   PubMed Web of Science ®Google Scholar
• Collins AJ, Li S, St Peter W, Death, hospitalization and economic associations among incident hemodialysis patients with hematochrit values of 36 to 39%. J Am Soc Nephrol 2001;12:2465-73
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2071-84
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoein. N Engl J Med 1998;339:584-90
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, Normalization of hemoglobin level in patients with chronic kidney disease who are receiving hemodialysis and epoetin. N Engl J Med 2006;355:2071-84
   PubMed Web of Science ®Google Scholar
• Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target hemoglobin concentrations in anemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Iurig JK. Secondary analysis of the CHOIR trial epoetin-alfa dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-8
   PubMed Web of Science ®Google Scholar
• Fishbane S, Bsarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007;2:1274-82
   PubMed Web of Science ®Google Scholar
• Messana JM, Chuang CC, Turenne M, Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Am J Kidney Dis 2009;53:503-12
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Ninomiya T, Zoungas S, Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomized controlled trials. Lancet 2009;373:1009-15
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration and Center for Drug Evaluation and Reaserch Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESAs) Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm
   Google Scholar
• Singh A. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. Semin Dial 2009;22:64-9
   PubMed Web of Science ®Google Scholar
• US Renal Data System: USRDS 2007 Annual Data Report Bethesda MD: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 2007
   Google Scholar
• Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-43
   PubMed Web of Science ®Google Scholar
• Laeson E Jr, Ofsthun N, Lazarus JM. Effects of variability in anemia management on hemoglobin outcomes in ESRD. Am J kidney Dis 2003;41:111-24
   PubMed Web of Science ®Google Scholar
• Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comobidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10
   PubMed Web of Science ®Google Scholar
• Gilbertson DT, Ebben JP, Foley RN, Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008;3:133-8
   PubMed Web of Science ®Google Scholar
• Yang W, Israni RK, Brunelli SM, Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-70
   PubMed Web of Science ®Google Scholar
• Fishbane S, Singh AK. Iron deficiency in non-dialysis chronic kidney disease. Kidney Int 2008; In press
   Google Scholar
• Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl 2006;69:513-18
   Google Scholar
• Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in hemodialysis patients. Nephrol Dial Transplantation 1996;11:1079-83
   PubMed Web of Science ®Google Scholar
• Canavese C, Grill A, De Costanzi E, How to save money for erythropoietin therapy by changing from “roller coaster” to continuous iron supplementtatioin. Nephron 1999;81:362-3
   PubMedGoogle Scholar
• Bolanos L, Castro P, Falcon TG, Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis and peritoneal dialysis patients. Am J Nephrol 2002;22:67-72
   PubMed Web of Science ®Google Scholar
• Schiesser D, Binet I, Tsinalis D, Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006;21:2841-5
   PubMed Web of Science ®Google Scholar
• Coyne DW, Kapoian T, Suki W, Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferring saturation: results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007;18:975-84
   PubMed Web of Science ®Google Scholar
• Kapoian T, O'Mara NB, Singh AK, Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372-9
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, Recombinant human erythropoietin's and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach M, Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach M. Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis? Blood, ASH Meeting 2007;110:1625 [abstract]
   Google Scholar
• Ross SD, Allen IE, Henry DH. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28:801-31
   PubMed Web of Science ®Google Scholar
• Aapro M, Coiffier B, Dunst J. Effect of treatment with epoetin beta on short-term tumour progression and survival in anemic patients with cancer: a meta-analysis. Br J Cancer 2006;95:1467-73
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, Venous thromoboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 2009;373:1532-42
   PubMed Web of Science ®Google Scholar
• Ludwig H, Crawford J, Osterborg A, Pooled analysis of individual patient-level data from all randomized, double-blind, placebo controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; In press
   Google Scholar
• Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin beta on survival, tumor progression and thrmboembolic events in patients with cancer: an updated meta-analysis of 12 randomized controlled studies including 2301 patients. Br J Cancer 2009;99:14-22
   Web of Science ®Google Scholar
• Aapro MT, Link M. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13:33-6
   PubMed Web of Science ®Google Scholar
• Nowrousian MR, Durst J, Vaupel P. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated. Strahelenther Onkol 2008;184:121-36
   PubMed Web of Science ®Google Scholar
• Fandrey J. Erythropoietin receptors on tumor cells: what do they mean? Oncologist 2008;13(Suppl 3):16-20
   PubMed Web of Science ®Google Scholar
• Miller CP, Lowe KA, Valliant-Saunders K, Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells 2009; In press
   Google Scholar
• Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol 2009;27:4217-26
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 2008;45:14-22
   PubMed Web of Science ®Google Scholar
• Jadersten M, Malcovati L, Dybedal I, Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndromne. J Clin Oncol 2008;26:3607-13
   PubMed Web of Science ®Google Scholar
• Groenveld HF, Januzzi JL, Damman K, Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-27
   PubMed Web of Science ®Google Scholar
• Van Der Meer P, Groenveld HF, Januzzi JL, Van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009; In press
   Google Scholar
• Timmer S, De Boer K, Knaapen P, The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail 2009;15:353-61
   PubMed Web of Science ®Google Scholar
• Kumar A, Domiv V. Why treat anemia in the preoperative period of joint replacement surgery with erythropoietin? Clev Clin J Med 2006;73:813-15
   Google Scholar
• Martinez V, Monsaingeon-Lion A, Cherif K, Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs. Blood J Anaesth 2007;99:794-800
   PubMed Web of Science ®Google Scholar
• Gonzalez-Porras JR, Colado E, Conde MP, An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med 2009;19:35-42
   PubMed Web of Science ®Google Scholar
• Livnah O, Stura EA, Johnson DL, Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1966;273:464-71
   Web of Science ®Google Scholar
• Wrighton NC, Farrell FX, Chang R, Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:458-64
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Hematide a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. Curr Opin Investig Drugs 2008;9:1034-47
   PubMed Web of Science ®Google Scholar
• Fan Q, Leuther KK, Holmes CP, Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-11
   PubMed Web of Science ®Google Scholar
• Woodburn KW, Schatz PJ, Fong KI, Preclinical safety and pharmacology of hematide, a peptidic erythropoiesis stimulating agent (ESA) in rats and monkeys. Drug Chem Toxicol 2008;31:229-44
   PubMed Web of Science ®Google Scholar
• Woodburn KW, Wilson SD, Fong K, Chronic preclinical safety evaluation of HematideTM, a pegylated peptidic erythropoiesis stimulating agent in monkeys. Haematologica 2008;93:1376-9
   PubMed Web of Science ®Google Scholar
• Woodburn KW, Wilson SD, Fong KL, Chronic pharmacological and safety evaluation of HematideTM, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents. Basic Clin Pharmacol Toxicol 2008;104:155-63
   PubMed Web of Science ®Google Scholar
• Stead RB, Lambert J, Wessels D, Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006;108:1830-4
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Tucker B, Yaqoob M, Hematide a synthetic peptide-basis erythropoietic stimulating agent, achieves correction of anemia and maintains Hb in patients with CKD not on dialysis. Ann Meet Am Soc Nephrol 2006;39: abstract F-FC079
   Google Scholar
• Besarab A, Zeig S, Geronemus R, Hematide, a synthetic peptide-based erythropoietic stimulating agent, maintains hemoglobin in hemodialysis patients previously treated with epoetin alfa (EPO). Natl Kidney Found Clin Meet Abst 24; April 10 – 14, 2007; Orlando, FL
   Google Scholar
• Bugelski PJ, Capocasale RJ, Makropoulos D, CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 2008;134:171-80
   PubMed Web of Science ®Google Scholar
• Sathyanarayana P, Houde E, Marshall D, CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pool. Blood 2009. In press
   Google Scholar
• Hsich MM, Linde NS, Wynter A, HIF hydroxylase inhibition results in endogenous erythropoietin unduction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007;110:2140-7
   PubMed Web of Science ®Google Scholar
• Bruegge K, Jelkmann W, Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 2007;14:1853-62
   PubMed Web of Science ®Google Scholar
• Fraisl P, Aragonés J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Discov 2009;8:139-52
   PubMed Web of Science ®Google Scholar
• Nakano Y, Imagawa S, Matsumoto K, Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 2004;104:4300-7
   PubMed Web of Science ®Google Scholar
• Liu Z, Stoll VS, DeVries PJ, A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 2007;110:2408-13
   PubMed Web of Science ®Google Scholar
• Lacy SE, DeVries PJ, Xie N, The potency of erythropoietin-mimic antibodies correlates inversely with affinity. J Immunol 2008;181:1282-7
   PubMed Web of Science ®Google Scholar
• Viatte L, Vaulont S. Hepcidin, the iron watcher. Biochimie 2009;91:1223-8
   PubMed Web of Science ®Google Scholar
• Hashizume M, Uchiyama Y, Horai M, Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int 2009; In press
   Google Scholar
• Clement FM, Klarenbach S, Tonelli M, The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease. Arch Intern Med 2009;169:1104-12
   PubMed Web of Science ®Google Scholar
• Corwin HL, Gettinger A, Fabian TC, Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76
   PubMed Web of Science ®Google Scholar